INmune Bio announces video detailing findings from Phase 2 MINDFuL trial

INmune Bio (INMB) announced that a video detailing the additional findings from the Phase 2 MINDFuL trial evaluating XPro, a novel selective soluble TNF inhibitor, will be published on the company’s YouTube Channel following the conclusion of Alzheimer’s Association International Conference, AAIC, in Toronto, Canada. This forthcoming video will offer an overview of the latest clinical insights shared during the Alzheimer’s Association International Conference. Viewers can expect an in-depth exploration of how XPro was evaluated within the MINDFuL study design, as well as the significance of the findings for patients, clinicians, and investors interested in the evolving landscape of Alzheimer’s disease therapies.